1. Home
  2. CRSP vs FULT Comparison

CRSP vs FULT Comparison

Compare CRSP & FULT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$51.20

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Logo Fulton Financial Corporation

FULT

Fulton Financial Corporation

HOLD

Current Price

$24.51

Market Cap

4.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
FULT
Founded
2013
1882
Country
Switzerland
United States
Employees
393
3400
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.1B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRSP
FULT
Price
$51.20
$24.51
Analyst Decision
Buy
Hold
Analyst Count
17
4
Target Price
$70.29
$21.75
AVG Volume (30 Days)
1.6M
2.0M
Earning Date
05-11-2026
04-22-2026
Dividend Yield
N/A
3.55%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
N/A
Revenue This Year
$807.72
$6.39
Revenue Next Year
$172.52
$5.52
P/E Ratio
N/A
$10.58
Revenue Growth
9169.85
N/A
52 Week Low
$44.12
$16.60
52 Week High
$78.48
$24.71

Technical Indicators

Market Signals
Indicator
CRSP
FULT
Relative Strength Index (RSI) 42.57 65.15
Support Level $47.92 $23.51
Resistance Level $59.61 $24.71
Average True Range (ATR) 3.39 0.45
MACD -0.83 -0.05
Stochastic Oscillator 12.78 82.92

Price Performance

Historical Comparison
CRSP
FULT

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About FULT Fulton Financial Corporation

Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.

Share on Social Networks: